Stevanato Group SpA

Stevanato Group reported second-quarter 2026 revenue of EUR 302 million, an 8% increase year over year, driven by a 9% rise in its Biopharmaceutical and Diagnostic Solutions segment. High-value solutions revenue grew 16% to EUR 135.9 million, representing 45% of total revenue, while adjusted EBITDA rose 21% to EUR 78.7 million with a margin of 26%. The company completed the divestiture of its California-based subsidiary Balda C. Brewer, recording EUR 12.2 million in one-time expenses, and updated its full-year revenue guidance to EUR 1.260 billion to EUR 1.280 billion, reflecting a EUR 15 million reduction from the sale and EUR 8 million in favorable currency translation. CEO Franco Stevanato highlighted the regulatory approval of the proprietary Alina variable-dose pen platform in several European countries as a key commercial milestone, and the company launched Deora, a novel multi-use fixed-dose pen injector system. Biologics revenue within the high-value solutions segment increased 30% year over year, and GLP-1 revenue accounted for approximately 22% to 23% of total company revenue.

TimesSquare Capital Management's U.S. Mid Cap Growth Strategy stated that market concerns over Stevanato Group S.p.A. may be overblown, despite a 32% share decline driven by fears that oral GLP-1 drug formulations could slow injectable product growth. The strategy noted that Stevanato has several multi-year contracts providing strong revenue visibility. Stevanato Group supplies drug containment, delivery, and diagnostic solutions to the biopharmaceutical industry. The strategy fell 7.72% net in the first quarter of 2026, underperforming the Russell Midcap Growth Index's 6.35% decline.